Doris Peterkin

Head, Vaccine Development at OncoPep

Doris has served in a variety of leadership roles for biopharmaceutical and healthcare companies including Genzyme (now Sanofi Genzyme). Most recently, Doris was Chief Executive Officer at Healagenics, a health-care technology firm focused on the wound-care market, and Vice President of Market Development at Antigenics (now Agenus), a cancer vaccine development company. Doris received her Bachelor of Science from Virginia Polytechnic Institute and State University and her Master of Business Administration from Boston University.


Org chart


Teams


Offices

This person is not in any offices


OncoPep

Through targeting multiple tumor-associated antigens with an investigational multi-peptide vaccine and a multi-tumor antigen adoptive (MTAA) T cell therapy, OncoPep’s T cell-focused technologies are designed to be used on their own or in combination with other immunotherapeutics.


Industries

Employees

11-50

Links